scholarly journals The Ultraviolet Index Is Well Estimated by the Terrestrial Irradiance at 310 nm

Sensors ◽  
2021 ◽  
Vol 21 (16) ◽  
pp. 5528
Author(s):  
Peter D. Kaplan ◽  
Emmanuel L. P. Dumont
Keyword(s):  
Bandpass Filter ◽  
Atmospheric Model ◽  
The United States ◽  
Spectral Irradiance ◽  
Uv Exposure ◽  
Uv Index ◽  
Non Melanoma Skin Cancer ◽  
Wide Range ◽  
Ultraviolet Index ◽  
Melanoma Skin

Ultraviolet (UV) exposure significantly contributes to non-melanoma skin cancer. In the context of health, UV exposure is the product of time and the UV Index (UVI), a weighted sum of the irradiance I(λ) over all wavelengths from λ = 250 to 400 nm. In our analysis of the United States Environmental Protection Agency’s UV-Net database of over 400,000 spectral irradiance measurements taken over several years, we found that the UVI is well estimated by 77 I310. To further understand this result, we applied an optical atmospheric model to generate terrestrial irradiance spectra and found that it applies across a wide range of conditions. An accurate UVI radiometer can be built from a photodiode covered by a bandpass filter centered at 310 nm.

scholarly journals Age distribution of patients with advanced non-melanoma skin cancer in the United States

2013 ◽  
Vol 305 (9) ◽  
pp. 845-850 ◽  
Author(s):  
Stacey Dacosta Byfield ◽  
Diana Chen ◽  
Yeun Mi Yim ◽  
Carolina Reyes
Keyword(s):  
Skin Cancer ◽  
Advanced Disease ◽  
Locally Advanced ◽  
Age Distribution ◽  
Specific Treatment ◽  
The United States ◽  
Non Melanoma Skin Cancer ◽  
Number Of Patients ◽  
Incident Cases ◽  
Melanoma Skin

Abstract The epidemiology of non-melanoma skin cancer (NMSC) is not well understood due to exclusion from most US cancer registries. Patients with at least two claims with a NMSC diagnosis (ICD-9-CM 173.xx) at least 60 days apart, or at least one claim for a NMSC-specific treatment from 1/2010 to 12/2010, were identified from a large US commercial insurance claims database and grouped into one of three cohorts: metastatic (MET), locally advanced (LA), or “all other”. MET patients had at least two claims with a metastasis code at least 30 days apart. LA patients had at least two visits to a medical oncologist, one diagnostic imaging service, two radiation therapy services, or one visit to two or more physician specialties. Remaining patients were “all other”. Incidence and prevalence of NMSC were calculated from among the total number of persons continuously enrolled in the plan during the study period and standardized to the 2010 US population. From among 6,610,256 patients, there were 47,451 incident cases of NMSC (MET n = 16, LA n = 387, all other n = 47,048). The age-adjusted incidence rate of 693 per 100,000 persons (2010 population) approximates to 2,139,535 total NMSC cases in the US (0.7 % of population). 671 prevalent cases had advanced disease (MET n = 43, LA n = 628); an age-adjusted rate of 0.6 and 10 per 100,000 US persons equivalent to 1,993 and 29,841 MET and LA cases, respectively. Although NMSCs rarely progress, the number of patients with advanced disease is significant. Further studies to determine proportions of advanced NMSC by subtype are needed.

scholarly journals P691 UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S433-S434
Author(s):  
Y. Wu ◽  
S. Ghaly ◽  
S. Kerr ◽  
K. Krishnaprasad ◽  
R. Prosser ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Skin Type ◽  
Uv Exposure ◽  
Skin Cancer Risk ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

scholarly journals Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

2011 ◽  
Vol 5 ◽  
pp. CMO.S5074 ◽  
Author(s):  
Bryan A. Faller ◽  
Trailokya N. Pandit
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Vinca Alkaloid ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Risks And Benefits ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with either cytotoxic chemotherapy and/or targeted therapies, has been established to provide benefit to patients with NSCLC in both the adjuvant and advanced disease settings. Vinorelbine, a semi-synthetic vinca-alkaloid has been extensively tested alone and in combination with other cytotoxic or targeted agents in the treatment of NSCLC. Its safety has been well established with neutropenia, anemia, nausea, and vomiting being the most frequently encountered toxicities. The data defining the risks and benefits of vinorelbine in the treatment of NSCLC will be summarized.

The collision tumor in the assessment of non-melanoma skin cancer caused by occupational UV exposure

2015 ◽  
Vol 13 (5) ◽  
pp. 461-463
Author(s):  
Silas Paras Soemantri ◽  
Martin Dörler ◽  
Markus Stücker ◽  
Eggert Stockfleth ◽  
Heinrich Dickel
Keyword(s):  
Skin Cancer ◽  
Collision Tumor ◽  
Uv Exposure ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

scholarly journals Risk of Non-Melanoma Skin Cancer in Association with Use of Hydrochlorothiazide-Containing Products in the United States

2021 ◽  
Author(s):  
Efe Eworuke ◽  
Nicole Haug ◽  
Marie Bradley ◽  
Austin Cosgrove ◽  
Tancy Zhang ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Incidence Rate ◽  
Proportional Hazards ◽  
The United States ◽  
Cox Proportional Hazards ◽  
Mitigation Strategies ◽  
Converting Enzyme Inhibitors ◽  
Non Melanoma Skin Cancer ◽  
Increased Risk ◽  
Melanoma Skin

Abstract Background European studies reported an increased risk of non-melanoma skin cancer associated with hydrochlorothiazide (HCTZ)-containing products. We examined the risks of basal cell (BCC) and squamous cell carcinoma (SCC) associated with HCTZ compared to angiotensin-converting enzyme inhibitors (ACEIs) in a US population. Methods We conducted a retrospective cohort study in the US Food and Drug Administration’s Sentinel System. From the date of HCTZ or ACEI dispensing, patients were followed until a SCC or BCC diagnosis requiring excision or topical chemotherapy treatment on or within 30 days after the diagnosis date; or a censoring event. Using Cox proportional hazards regression models, we estimated the hazard ratios (HRs), overall and separately by age, sex, and race. We also examined site- and age-adjusted incidence rate ratios (IRRs) by cumulative HCTZ dose within the matched cohort. Results Among 5.2 million propensity-score matched HCTZ and ACEI users, the incidence rate (per 1,000 person-years) of BCC was 2.78 and 2.82 respectively, and 1.66 and 1.60 for SCC. Overall, there was no difference in risk between HCTZ and ACEIs for BCC (HR = 0.99, 95% CI = 0.97–1.00), but an increased risk for SCC (HR = 1.04, 95% CI = 1.02–1.06). HCTZ use was associated with higher risks of BCC (HR = 1.09, 95% CI = 1.07–1.11) and SCC (HR = 1.15, 95% CI = 1.12–1.17) among Caucasians. Cumulative HCTZ dose ≥50,000mg was associated with an increased risk of SCC in the overall population (IRR =1.19, 95% CI = 1.05–1.35) and among Caucasians (IRR = 1.27, 95% CI = 1.10–1.47). Conclusions Among Caucasians, we identified small increased risks of BCC and SCC with HCTZ compared to ACEI. Appropriate risk mitigation strategies should be taken while using HCTZ.

scholarly journals Characteristics of non-melanoma skin cancer depending upon occupational solar UV exposure dosage

2020 ◽  
Vol 67 (1) ◽  
pp. 37-43
Author(s):  
Alexandra-Irina Butacu ◽  
◽  
Marc Wittlich ◽  
Swen Malte John ◽  
Sabina Zurac ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Uv Exposure ◽  
Non Melanoma Skin Cancer ◽  
Exposure Dosage ◽  
Solar Uv ◽  
Melanoma Skin

UV Exposure and Skin Type are More Important than Thiopurine Exposure for Non-Melanoma Skin Cancer Risk in IBD

2017 ◽  
Vol 152 (5) ◽  
pp. S576 ◽  
Author(s):  
Yang Wu ◽  
Simon Ghaly ◽  
Stephen Kerr ◽  
Krupa Krishnaprasad ◽  
Deborah Martins ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Skin Type ◽  
Uv Exposure ◽  
Skin Cancer Risk ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Skin Malignancies Associated with HYDROXYUREA Use in MYELOPROLIFERATIVE DISORDERs and Sickle Cell Patients: Incidence and Significance.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4969-4969
Author(s):  
Maguy Chiha ◽  
Mohamad Younes ◽  
Karim Arnaout ◽  
Amr Hanbali
Keyword(s):  
Skin Cancer ◽  
General Population ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Case Reports ◽  
Myeloproliferative Disorders ◽  
The United States ◽  
Non Melanoma Skin Cancer ◽  
Skin Cancers ◽  
Melanoma Skin

Abstract Abstract 4969 BACKGROUND Hydroxyurea (HU) is one of the mainstay agents used to treat myeloproliferative disorders as well as sickle cell anemia. There has been lately increasing reports of secondary skin malignancies in patients receiving Hydroxyurea therapy but the literature consists essentially of case reports. Current incidence of melanoma skin cancer in the general population in the United States is 15 per 100 000 person, and of non melanoma skin cancer is 230 per 100 000 lightly pigmented individuals and 3.4 per 100 000 darkly pigmented individuals. METHODS We reviewed 292 charts of patients treated with HU in our institution. 237 patients carried a diagnosis of myeloproliferative disorder, 14 patients were treated for sickle cell anemia and 41 patients were being treated with HU for HIV as part of a regimen to decrease viral load. Charts were reviewed looking for development of skin malignancies. RESULTS Among the patients with sickle cell anemia, the incidence of skin cancer was nil. Among the patients with HIV there were 2 cases of non melanoma skin cancer. Among patients with myeloproliferative disorders, there were 16 cases of skin cancer. The pathology was non-melanoma skin cancer. Subgroup analysis based on skin phenotype revealed that the incidence was higher than the general population in both dark and light-skinned individuals: the rate was 0.9434 per 100 among the dark skinned individuals, statistically significant when compared to the established rate of 0.0034 per 100 dark-skinned individual in the general population. Similarly among light-skinned individuals, the calculated rate was 12.0968 per 100-person, which is statistically significant compared to the rates in light-skinned individuals in the general population of 0.2300 per 100 person with a p-value of 0.001. CONCLUSION Our study showed a significantly higher incidence of non-melanoma skin cancer among patients treated with HU. While HU is well known to have cutaneous side effects in terms of hyperpigmentation, skin ulcers, scaling or skin atrophy, its implication in skin cancers had only been in the form of case reports. Our study thus highlights a true risk of skin malignancies with HU. It is worth noting though that there were only non-melanoma skin cancers, which are non-aggressive, localized and treatable. Thus this heightened incidence of skin cancer does not appear to bear a mortality or morbidity burden on patients treated with HU. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document